Free Trial

Panbela Therapeutics (PBLA) Competitors

Panbela Therapeutics logo
$0.01 +0.00 (+0.91%)
As of 10/10/2025 11:27 AM Eastern

PBLA vs. NCNA, SYRS, NKGN, SMFL, VRPX, SCPS, VAXX, TRVN, ARDS, and NAVB

Should you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include NuCana (NCNA), Syros Pharmaceuticals (SYRS), NKGen Biotech (NKGN), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Trevena (TRVN), Aridis Pharmaceuticals (ARDS), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

Panbela Therapeutics vs. Its Competitors

NuCana (NASDAQ:NCNA) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Panbela Therapeutics' return on equity of 0.00% beat NuCana's return on equity.

Company Net Margins Return on Equity Return on Assets
NuCanaN/A -592.28% -208.68%
Panbela Therapeutics N/A N/A -302.61%

NuCana has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.

NuCana is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuCanaN/AN/A-$24.28M-$646.16-0.01
Panbela TherapeuticsN/AN/A-$25.26M-$71.130.00

44.0% of NuCana shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 31.2% of NuCana shares are owned by insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuCana
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Panbela Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, NuCana had 2 more articles in the media than Panbela Therapeutics. MarketBeat recorded 2 mentions for NuCana and 0 mentions for Panbela Therapeutics. NuCana's average media sentiment score of 0.95 beat Panbela Therapeutics' score of 0.00 indicating that NuCana is being referred to more favorably in the media.

Company Overall Sentiment
NuCana Positive
Panbela Therapeutics Neutral

Summary

NuCana beats Panbela Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Panbela Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBLA vs. The Competition

MetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$54K$787.62M$6.05B$10.30B
Dividend YieldN/A4.84%5.73%4.82%
P/E Ratio0.001.2885.1427.10
Price / SalesN/A29.85607.17133.24
Price / CashN/A17.6425.7730.18
Price / Book0.007.5412.646.69
Net Income-$25.26M-$7.59M$3.32B$276.55M
7 Day PerformanceN/A9.26%-0.07%-0.40%
1 Month PerformanceN/A18.72%8.70%6.53%
1 Year PerformanceN/A-12.60%78.24%41.04%

Panbela Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PBLA
Panbela Therapeutics
0.0902 of 5 stars
$0.01
+0.9%
N/A-96.9%$54KN/A0.006
NCNA
NuCana
1.3712 of 5 stars
$7.02
+38.2%
N/A-98.6%$150KN/A-0.0130High Trading Volume
SYRS
Syros Pharmaceuticals
3.7953 of 5 stars
$0.01
flat
$1.00
+19,900.0%
-99.7%$134K$386K0.00120
NKGN
NKGen Biotech
0.1324 of 5 stars
$0.00
+150.0%
N/A-96.4%$22KN/A0.00N/AGap Up
SMFL
Smart for Life
N/A$0.00
+25.0%
N/A-93.7%$18K$11.11M0.00110Gap Up
VRPX
Virpax Pharmaceuticals
0.0509 of 5 stars
$0.01
flat
N/A-99.8%$14KN/A0.007Gap Up
SCPS
Scopus BioPharma
N/A$0.00
flat
N/AN/A$13KN/A0.009
VAXX
Vaxxinity
N/A$0.00
-99.0%
N/A-97.5%$13KN/A0.0090Gap Down
TRVN
Trevena
1.6174 of 5 stars
$0.01
flat
$5.00
+41,566.7%
-99.4%$12K$443K0.0040
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat
N/AN/A$11KN/A0.0030High Trading Volume
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13K0.0010

Related Companies and Tools


This page (NASDAQ:PBLA) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners